medi6570
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 27, 2018 (NCT03654313)
Timeline
Indications
Mechanism of action
- LDL receptorINHIBITOR
LDLR inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04610892 | Phase 2 | Nov 4, 2020 | AstraZeneca, Thrombolysis in Myocardial Infarction Study Group |
| NCT03654313 | Phase 1 | Sep 27, 2018 | MedImmune |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 1 | 1 | 2020 |
| MedImmune | For profit | 1 | 1 | 1 | 2018 |
| Thrombolysis in Myocardial Infarction Study Group | Academic/Hospital | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1